GLP-1 Medication Contracts

Our Eligibility & Screening Criteria in Weight Loss Drug Cases

Atraxia Media has extensive experience delivering contracts to legal clients based on their specific eligibility criteria. We have become knowledgeable about cases of individuals who took weight loss drugs like Ozempic, Wegovy, and Mounjaro and later developed severe GI issues, vision loss, and other conditions. We will use all these resources to aid you in launching your weight loss drug campaign and get signed contracts delivered to your law firm.

Screening

Our team is ready to implement a retaining campaign that entails the following:

• Pre-screening. We are well aware that not every person who reaches out to you meets your eligibility criteria, and this is where our team of professionals comes in. Atraxia Media wants to help you save time by assessing the situation of each client, which is why our team will efficiently take care of the pre-screening of prospective clients to determine whether they are a good fit for your law firm.
• Screening each case. With a thorough comprehension of your eligibility criteria, we will screen each potential client by asking some simple questions and conducting interviews to determine whether their case would be suitable for your law firm. Our main goal for this step is to get to the core of each case to differentiate between eligible and ineligible clients.
• Following up with potential clients. At Atraxia Media, we want to maximize every interaction and build connections with prospective clients. We will follow up with everyone who seems to qualify for filing a weight loss drug claim with the assistance of your law firm. In our follow-up strategy, we take into account the availability of prospective clients along with recent developments in weight loss drug lawsuits.
• Delivering signed contracts to your law firm. If you decide to work with our team of professionals, you are bound to receive a constant influx of signed contracts from us. Our team is committed to providing you with the weight loss contracts you need.
• Increasing your volume of prospective claimants. Atraxia Media has been working on increasing the number of eligible cases a law firm receives for a few decades now. We guarantee that our team has the experience necessary to ensure you will observe a significant increase in the volume of your clients.
• Running in-house marketing strategies that generate cases. Due to our internal intake department, we receive the leads in real time. We can immediately proceed with the evaluation of leads based on your eligibility criteria.
• Getting potential weight loss drugs (GLP-1 RA) plaintiffs exclusively to your law firm. Currently, plaintiffs involved in weight loss drug cases are in high demand. As more developments on the GLP-1 drugs come to light, we expect to see more claimants in need of representation. We will go to great lengths to discover the best clients for your law firm.

Eligibility Evaluation

People who are eligible to file a GLP-1 RA drug claim must meet the following criteria:

• They must have not received a diagnosis of gastroparesis, bowel obstruction, or vision loss in the past.
• They must have taken the GLP-1 drug as prescribed by their doctor.
• They must have developed gastroparesis, bowel obstruction, or NAION as a result of taking the drug.

If your law firm is seeking a marketing partner to devise a strong and effective campaign to attract weight loss drug clients, Atraxia Media is the ideal company for you. Our team has over two decades of experience in marketing and advertising for legal clients, having assisted numerous law firms with outstanding results, so we have the necessary knowledge and resources to help you. We provide cost-effective, transparent strategies meant to find the perfect weight loss drug claimants for you.

Weight Loss Drugs (GLP-1 RA) Facts & History

Unlike insulin substitutes that are used for diabetes treatment, GLP-1 RA drugs do not contain insulin. Instead, GLP-1 RA drugs mimic a natural hormone in the body that is usually released after consuming a full meal. It mimics the effect of the GLP-1 hormone that tells the pancreas to release insulin, leaving patients feeling less hungry and more full for a longer period of time. These drugs cause patients to have lower blood glucose levels and to lose body weight. The active ingredient of a GLP-1 drug can be semaglutide, liraglutide, tirzepatide, or dulaglutide.

One in eight (12%) adults in the U.S. have taken a GLP-1 RA drug, according to a KFF survey of nearly 1,500 individuals. Most adults take GLP-1 medications for chronic conditions, particularly diabetes, but about four in ten adults surveyed in the KFF Health Tracking Poll said they were taking GLP-1 drugs to lose weight.

While GLP-1 RA drugs have become popular as "weight loss drugs" or "weight loss injections," not all of them are made for treating obesity. Drugs like Ozempic and Mounjaro are only approved for type 2 diabetes treatment. In fact, only Wegovy (semaglutide), Zepbound (tirzepatide), and Saxenda (liraglutide) are currently approved for weight loss management as of 2025.

MDL 3094 - GLP-1 RAS PRODUCTS LIABILITY LITIGATION

History:

2025:

On May 14, 2025, there will be a Rule 702 evidentiary hearing to determine the types of expert testimonies that will be accepted at the GLP-1 trials.

With the recent popularity of weight loss drugs, especially from 2022 to the present, more cases of GLP-1 RAs are expected to surface. These patients would need representation in filing claims for their injuries.

By March 2025, the MDL has had over 1,521 pending cases. The MDL focuses on gastrointestinal injuries from GLP-1 RA drugs and includes the following drugs:

• semaglutide (Ozempic)
• semaglutide (Wegovy)
• tirzepatide (Mounjaro)
• tirzepatide (Zepbound)
• dulaglutide (Trulicity)
• liraglutide (Victoza)
• liraglutide (Saxenda) - added to MDL on December 12, 2024

2024:

In February 2024, at least 55 lawsuits were centralized in Pennsylvania's Eastern District to what would be known as the Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation or Multidistrict Litigation No. 3094 (MDL 3094).

2023:

On August 2, 2023, the first GLP-1 RA drug lawsuit was filed by Jaclyn Bjorklund, a 44-year-old woman from Louisiana, against Novo Nordisk, the manufacturer of Ozempic, alleging her gastroparesis is the result of her taking the medication. Her attorneys claim that she used the drug for over a year. The manufacturer is accused based on failing to warn of the risk of severe gastrointestinal events that could be caused by taking Ozempic. According to the lawsuit, Bjorklund has suffered from "severe vomiting, stomach pain, and gastrointestinal burning. The side effects reportedly required her to be hospitalized for stomach issues, including emergency room visits.